Patent Application
20220170096
The present invention relates to a newly identified AHR-activating enzyme and uses thereof as a marker in diagnosis and therapy, for example for selecting patients for treatment with IL4I1 modulating interventions and monitoring of therapy response.
IL4I1 is an L-amino acid oxidase that catalyzes the oxidative deamination of L-amino acids to alpha-keto acids while producing hydrogen peroxide and ammonia (1). Initially discovered as an immediate-early IL4-inducible gene in B cells (2, 3), IL4I1 was later identified also in macrophages and dendritic cells (4). In addition, IL4I1 is expressed in human malignancies either in the neoplastic cells themselves, or in tumor-associated macrophages (5). IL4I1 inhibits T cell proliferation (4, 6), which has mainly been attributed to its H2O2 production. Moreover, IL4I1 has been implicated in Th17 cell (7) and regulatory T cell (8) differentiation, which is known to be modulated by AHR activation (9-11).
Currently, only very little is known about the therapeutic implications of IL4I1-associated conditions. This can be exemplified by the presence of only one patent publication, WO 2016/040488, which discloses methods of promoting myelin formation in central nervous system (CNS) tissue in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of IL4I1 protein.
The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor involved in the regulation of diverse processes such as embryogenesis, vasculogenesis, metabolism, immunity and cancer. In preclinical studies, AHR activation by tryptophan metabolites generated through indoleamine-2,3-dioxygenase (IDO1) and/or tryptophan-2,3-dioxygenase (TDO2) promoted tumor progression by enhancing the motility, anoikis resistance and clonogenic survival of the tumor cells as well as by suppressing anti-tumor immune responses (12). AHR target gene expression is context specific (13), and the introduction of new biomarkers of AHR activation that efficiently detect AHR activation across different cells/tissues and in response to diverse AHR ligands is required. Furthermore, the functional implications of IL4I1 modulation and AHR modulation share many common pathways and cross talk, entailing the importance of considering IL4I1 as a potential biomarker for conditions of AHR modulation and vice versa.
In a first aspect thereof, the present invention relates to a method for detecting a modulation of AHR in a cell or a subject, comprising detecting a change of the biological state of IL4I1 in said cell or a biological sample derived from said subject, wherein a change in said biological state of IL4I1 in said cell or sample, when compared to a control cell or sample, e.g. a sample derived from a healthy subject, a patient or patient group, indicates an IL4I1-related modulation of AHR in said cell or subject.
In a second aspect thereof, the present invention provides an in vitro method for screening for at least one potential modulator of the expression and/or biological activity of IL4I1, comprising contacting a sample comprising IL4I1 or a cell expressing IL4I1 with at least one candidate modulator compound, and detecting a modulation of said IL4I1, wherein said modulation identifies a potential modulator of the expression and/or biological activity of IL4I1.
Preferably, the method is a method for screening for at least one modulator of the biological state of IL4I1, comprising contacting at least one candidate modulator compound with a biological sample and detecting a change of said biological state of IL4I1 in a biological sample, wherein a change in the biological state of said IL4I1 in the presence of said at least one modulator compared to the absence of said at least one modulator identifies a modulator.
In a third aspect thereof, the present invention relates to a method for monitoring the modulation of the biological state of IL4I1 in response to at least one compound, comprising performing a method according to the present invention on a biological sample that was contacted with at least one compound, and wherein said biological sample is compared to a control sample that was not contacted with said compound.
In a sub-aspect of this method, the present invention relates to a method for monitoring the biological state of AHR in a cell, comprising providing at least one compound to said cell and detecting the change in the biological state, such as the expression and/or biological function of IL4I1 in said cell in response to said at least one compound, wherein a change in the biological state, such as in the expression or biological function in the presence of said at least one compound compared to the absence of said at least compound indicates an effect of said at least one compound on said biological state of AHR in a cell.
In another preferred aspect of the present invention, the invention then relates to a method for treating and/or preventing an AHR-related disease or condition in a cell, for example in a patient in need of said treatment, comprising performing a method according to the present invention, and providing a suitable treatment to said patient, wherein said treatment is based, at least in part, on the results of the method according to the present invention, such as providing a compound as identified or monitoring a treatment comprising the method(s) as described herein.
Another important aspect of the present invention relates to a diagnostic kit comprising materials for performing a method according to the present invention in one or separate containers, optionally together with auxiliary agents and/or instructions for performing said method. Another important aspect of the present invention then relates to the use of said diagnostic kit in a method according to the present invention.
Finally, the invention relates to the use of the biomarker IL4I1 for screening for modulators according to the present invention or for monitoring according to the present invention.
Generally preferred are the human variants of the biomarker IL4I1, or closely related species, like the ones from other primates or mammals.
Other aspects and advantages can be readily derived from reading the following description and the non-limiting examples.
The present inventors—while investigating the role of tryptophan degrading enzymes in modulating AHR activity—discovered that the expression of IL4I1, a tryptophan-degrading enzyme expressed in human cancers (
As mentioned above, in experiments as performed in the context of the present invention, the new biomarker IL4I1 was identified as a new component upstream of the AHR. This enables an in vitro method for screening for at least one modulator of the biological state of IL4I1, comprising contacting at least one candidate modulator compound with a biological sample and detecting a change of said biological state of IL4I1 in a biological sample, wherein a change in the biological state of said IL4I1 in the presence of said at least one modulator compared to the absence of said at least one modulator identifies a modulator. A modulator can be an activator (inducer) or inhibitor of said biological state of IL4I1.
In one alternative, the method for screening for a potential modulator of the expression and/or biological activity of IL4I1 comprises contacting a sample comprising IL4I1 or a cell expressing IL4I1 with at least one candidate modulator compound and detecting a binding of said modulator to said IL4I1, wherein said binding identifies a potential modulator of the expression and/or biological activity of IL4I1. This method preferably further comprises the step of detecting the expression and/or biological activity of IL4I1 in said cell or the biological activity of IL4I1 in said sample, wherein a change in the expression or biological activity of IL4I1 in the presence of said at least one compound compared to the absence of said at least one compound identifies a modulator.
Preferred is such a method according to the present invention, wherein said modulator is selected from an inhibitor or an inducer of said expression or biological activity.
Another important aspect of the present invention then relates to a method for diagnosing an AHR-related disease or condition in a cell and/or a subject, comprising detecting a change of the biological state of IL4I1 in a biological sample derived from said cell and/or subject, wherein a change in said biological state of IL4I1 in said sample, when compared to a control sample, indicates an AHR-related physiological or pathological condition in said cell and/or subject.
In one aspect, said method comprises detecting the expression or biological function of IL4I1 in a cell/tissue/biological fluid, wherein a change in the expression or biological function in said compartments, in particular expression or activation, when compared to a healthy or other suitable control sample, indicates an AHR-related disease or condition. Such a change can be at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80% or at least about 90% or more of up or down regulation of expression or biological function, when compared with a suitable control, such as the value in a healthy cell or a sample derived from a healthy person or group of individuals, or when compared to an internal standard, like a housekeeping gene. In the context of the present invention, the term “about” shall mean +/−10% of the given value, unless indicated otherwise.
In the context of the present invention, it was found that said modulation of AHR in a cell or subject as detected through detecting a change of the biological state of IL4I1 is indicative for an AHR-related physiological or pathological condition in said cell or subject. Preferably, the AHR-associated physiological or pathological condition to be stratified and/or diagnosed is selected from intoxication, cancer, autoimmune disorders, degeneration, inflammation, infection, metabolic diseases and conditions, angiogenesis, drug metabolism, hematopoiesis, lipid metabolism, cell motility, immune modulation, and stress conditions, for example, biological, mechanical and environmental stresses.
Preferred is a method according to the present invention, wherein said biological state as detected is selected from mutations, nucleic acid methylation, copy numbers, expression, amount of protein, protein modifications, cellular localization, metabolites, in particular metabolites as produced by IL4I1, such as, for example, tryptophan degradation products, tryptophan metabolites including kynurenic acid, and the biological activity of IL4I1.
In a preferred embodiment, in the method according to the present invention said biological state of IL4I1 is detected indirectly through a change of abundance or biological activity of at least one metabolite biomarker according to table 1 as herein below, wherein a change in said expression or biological activity of said at least one biomarker when compared to a control sample indicates a change of the biological state of IL4I1 in said sample.
In the method according to the present invention, said biological sample can be selected from a suitable sample comprising biological fluids, human cells, tissues, whole blood, cell lines, cellular supernatants, primary cells, IPSCs, hybridomas, recombinant cells, stem cells, and cancer cells, bone cells, cartilage cells, nerve cells, glial cells, epithelial cells, skin cells, scalp cells, lung cells, mucosal cells, muscle cells, skeletal muscles cells, striated muscle cells, smooth muscle cells, heart cells, secretory cells, adipose cells, blood cells, erythrocytes, basophils, eosinophils, monocytes, lymphocytes, T-cells, B-cells, neutrophils, NK cells, regulatory T-cells, dendritic cells, Th17 cells, Th1 cells, Th2 cells, myeloid cells, macrophages, monocyte derived stromal cells, bone marrow cells, spleen cells, thymus cells, pancreatic cells, oocytes, sperm, kidney cells, fibroblasts, intestinal cells, cells of the female or male reproductive tracts, prostate cells, bladder cells, eye cells, corneal cells, retinal cells, sensory cells, keratinocytes, hepatic cells, brain cells, kidney cells, and colon cells, and the transformed counterparts of said cells or tissues.
Preferred is a method according to the present invention, wherein said subject is selected from a mammalian subject, in particular a human subject, in particular a human patient suffering from an AHR-related physiological or pathological condition. Said control sample can be selected from a sample as described above.
Another aspect of the invention then relates to a method for monitoring the modulation of the biological state of IL4I1 in response to at least one compound, comprising performing a method according to the present invention on a biological sample that was contacted with an amount of said at least one compound, and wherein said biological sample is compared to a control sample that was not contacted with said amount of said compound.
Preferred is such a method for monitoring an AHR-related disease or condition in a cell, comprising providing at least one compound to said cell and detecting the change in the expression or biological function of IL4I1 in said cell in response to said at least one compound, wherein a change in the expression or biological function in the presence of said at least one compound compared to the absence of said at least compound indicates an effect of said at least one compound on said IL4I1-related disease or condition.
In the context of the invention, the AHR-related disease or condition can be selected from at least one of intoxication, cancer, autoimmune disorders, degeneration, inflammation, infection, metabolic diseases and conditions, angiogenesis, drug metabolism, hematopoiesis, lipid metabolism, cell motility, senescence, immune modulation, stress conditions, for example, biological, mechanical and environmental stresses, and AHR modulation.
In some embodiments, the condition is cancer. In some embodiments, the cancer is selected from Adrenocortical carcinoma (ACC), Bladder Urothelial Carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC), Esophageal carcinoma (ESCA), Glioblastoma multiforme (GBM), Head and Neck squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH), Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell carcinoma (KIRP), Brain Lower Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Mesothelioma (MESO), Ovarian serous cystadenocarcinoma (OV), Pancreatic adenocarcinoma (PAAD), Pheochromocytoma and Paraganglioma (PCPG), Prostate adenocarcinoma (PRAD), Rectum adenocarcinoma (READ), Sarcoma (SARC), Skin Cutaneous Melanoma (SKCM), Stomach adenocarcinoma (STAD), Testicular Germ Cell Tumors (TGCT), Thyroid carcinoma (THCA), Thymoma (THYM), Uterine Corpus Endometrial Carcinoma (UCEC), Uterine Carcinosarcoma (UCS), and Uveal Melanoma (UVM).
Methods according to the present invention are provided to, in one aspect, seek for modulators and elucidate effects thereof on the biomarker IL4I1 as identified. Examples of such compounds to be identified can be selected from a small molecule, a peptide, and a library of said compounds. Said compound as identified (screened) is selected from small chemical molecules, peptides, antibodies, and short interfering RNAs. Preferably, said compound can be selected from a proteinaceous domain, a small molecule, a peptide, an environmental substance, probiotic, toxin, aerosol, medicine, nutrient, galenic composition, plant extract, volatile compound, homeopathic substance, incense, pharmaceutical drug, vaccine, a compound or compound mixture derived from organisms, for example animals, plants, fungi, bacteria, archaea, a chemical compound, a compound used in food or cosmetic industry, and a library of said compounds.
Identification and screening using the biomarkers as disclosed herein can be done using respective methods known in the art, preferably using recombinantly produced proteins of the biomarkers, and/or recombinant cell models. For this, the biomarkers can be labeled, e.g. using chemical dyes or fluorescent markers. Additionally, enzymes can be used, optionally in the form of fusions with the biomarker to be screened. Preferably, said method is also amenable to automatization, and said screening is preferably assessed in an automated and/or high-throughput format.
Another aspect then relates to the use of at least one biomarker of IL4I1 for screening for modulators according to the present invention or for monitoring according to the present invention or for testing the biological safety according to the present invention or for a diagnosis according to the present invention.
In another preferred aspect of the present invention, the invention then relates to a method of treating and/or preventing an AHR-related disease or condition in a cell in a patient in need of said treatment, comprising performing a method according to the present invention, and providing a suitable treatment to said patient, wherein said treatment is based, at least in part, on the results of the method according to the present invention, such as providing a compound as identified or monitoring a treatment.
In the context of the present invention, any biological sample comprising the marker protein IL4I1 (or functionally relevant parts thereof), or a sample comprising cells, comprising the marker protein IL4I1 (or functionally relevant parts thereof), e.g. obtained from a cancer patient, or a sample comprising at least one of the metabolites produced downstream of IL4I1, for example as shown in Table 1, can be used, as long as it contains (or is presumed to contain) at least one of the biomarker(s) to be used in the analysis and/or screen. Preferably, the biological sample is selected from a sample comprising biological fluids comprising biomarkers, cells, a suitable sample comprising biological fluids, human cells, tissues, whole blood, cell lines, cellular supernatants, primary cells, IPSCs, hybridomas, recombinant cells, stem cells, and cancer cells, bone cells, cartilage cells, nerve cells, glial cells, epithelial cells, skin cells, scalp cells, lung cells, mucosal cells, muscle cells, skeletal muscles cells, striated muscle cells, smooth muscle cells, heart cells, secretory cells, adipose cells, blood cells, erythrocytes, basophils, eosinophils, monocytes, lymphocytes, T-cells, B-cells, neutrophils, NK cells, regulatory T-cells, dendritic cells, Th17 cells, Th1 cells, Th2 cells, myeloid cells, macrophages, monocyte derived stromal cells, bone marrow cells, spleen cells, thymus cells, pancreatic cells, oocytes, sperm, kidney cells, fibroblasts, intestinal cells, cells of the female or male reproductive tracts, prostate cells, bladder cells, eye cells, corneal cells, retinal cells, sensory cells, keratinocytes, hepatic cells, brain cells, kidney cells, and colon cells, and the transformed counterparts of said cells or tissues. The sample can also be selected from tumor tissue (tumor or metastases), biopsies, whole blood, peripheral blood, or fractions thereof, serum, buffy coat, lymphatic fluid, urine, bone marrow, heparinized whole blood, and frozen samples thereof, such as frozen heparinized whole blood. The cells to be used in the methods according to the present invention can be recombinant or non-recombinant, and express cell-foreign proteins, depending on the desired purpose and circumstances. Totipotent human embryonic stem cells may be excluded, if necessary. The sample can also be a combined sample from a group of subjects, for example, a patient group.
Another aspect of the present invention then relates to a method for producing a pharmaceutical preparation, wherein said compound/modulator as identified (screened) is further formulated into a pharmaceutical preparation by admixing said (at least one) compound as identified (screened) with a pharmaceutically acceptable carrier. Pharmaceutical preparations can be preferably present in the form of injectables, tablets, capsules, syrups, elixirs, ointments, creams, patches, implants, aerosols, sprays and suppositories (rectal, vaginal and urethral). Another aspect of the present invention then relates to a pharmaceutical preparation as prepared according to the invention.
In another aspect of the present invention, the invention then relates to a diagnostic kit comprising materials for performing a method according to the present invention as herein in one or separate containers, optionally together with auxiliary agents and/or instructions for performing said method according to the present invention.
“Treatment” shall mean a reduction and/or amelioration of the symptoms of the disease. An effective treatment achieves, for example, a shrinking of the mass of a tumor and the number of cancer cells. A treatment can also avoid (prevent) and reduce the spread of the cancer, such as, for example, affect metastases and/or the formation thereof. A treatment may be a naïve treatment (before any other treatment of a disease had started), or a treatment after the first round of treatment (e.g. after surgery or after a relapse). The treatment can also be a combined treatment, involving, for example, chemotherapy, surgery, and/or radiation treatment.
In the methods of the present invention, in general the biomarkers can be detected and/or determined using any suitable assay. Detection is usually directed at the qualitative information (“marker yes-no”), whereas determining involves analysis of the quantity of a marker (e.g. expression level and/or activity). Detection is also directed at identifying for example mutations that cause altered functions of individual markers. The choice of the assay(s) depends on the parameter of the marker to be determined and/or the detection process. Thus, the determining and/or detecting can preferably comprise a method selected from subtractive hybridization, microarray analysis, DNA sequencing, RNA sequencing, qPCR, ELISA, IP, PLA, BiFC, HPLC, WB, enzymatic activity tests, fluorescence detection, cell viability assays, for example an MTT assay, phosphoreceptor tyrosine kinase assays, phospho-MAPK arrays and proliferation assays, for example the BrdU assay, proteomics, cytokine arrays, and mass spectrometry.
Preferably, said method is also amenable to automation, and said activity and/or expression is preferably assessed in an automated and/or high-throughput format. Usually, this involves the use of chips and respective machinery, such as robots.
Another aspect of the instant disclosure is directed to methods for determining the AHR activation state of a biological sample. In some embodiments, the biological sample is taken from a subject. In some embodiments, a biological state is determined/measured for Interleukin 4-Induced gene 1 (IL4I1).
In some embodiments, the method for determining AHR activation signature for a condition comprises: (a) obtaining a biological sample from a subject; (b) determining, in the biological sample, a biological state of IL4I1; (c) determining, in a control cell, the biological state of IL4I1; (d) comparing he biological state in step (b) to the biological state in step (c); and (e) determining the AHR activation state of biological sample based on the comparing.
In some embodiments, the biological state detected at step (b) is RNA expression. In some embodiments, the detecting a biological state comprises measuring levels of the biological state. In some embodiments, RNA expression of a biomarker is detected by methods known in the art including, but not limited to, qPCR, RT-qPCR, RNA-Seq, and in-situ hybridization.
In some embodiments, the method further comprises treating the subject with an AHR signaling modulator (also “AHR modulator”). In some embodiments, the AHR signaling modulator is administered every day, every other day, twice a week, once a week once a month or twice a month. In some embodiments, the AHR signaling modulator is administered together with other drugs as part of a combination therapy.
An “AHR signaling modulator” or an “AHR modulator” as used herein, refers to a modulator which affects AHR signaling in a cell. In some embodiments, an AHR signaling modulator exhibits direct effects on AHR signaling. In some embodiments, the direct effect on AHR is mediated through direct binding to AHR. In some embodiments, a direct modulator exhibits full or partial agonistic and/or antagonistic effects on AHR. In some embodiments, an AHR modulator is an indirect modulator.
In some embodiments, an AHR signaling modulator is a small molecule compound. The term “small molecule compound” herein refers to small organic chemical compound, generally having a molecular weight of less than 2000 daltons, 1500 daltons, 1000 daltons, 800 daltons, or 600 daltons.
In some embodiments, an AHR modulator comprises a 2-phenylpyrimidine-4-carboxamide compound, a sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamide compound, a 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamide compound, a 2-hetarylpyrimidine-4-carboxamide compound, a 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compound, a 2-heteroaryl-3-oxo-2,3-dihydro-4-carboxamide compound, PDM 2, 1,3-dichloro-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-benzene, α-Naphthoflavone, 6, 2′,4′-Trimethoxyflavone, CH223191, a tetrahydropyridopyrimidine derivative, StemRegenin-1, CH223191, GNF351, CB7993113 HP163, PX-A590, PX-A548, PX-A275, PX-A758, PX-A446, PX-A24590, PX-A25548, PX-A25275, PX-A25758, PX-A26446, an Indole AHR inhibitor, and an oxazole-containing (OxC) compound.
In some embodiments, a direct AHR modulator comprises:
In some embodiments, indirect AHR modulators affect AHR activation through modulation of the levels of AHR agonists or antagonists.
In some embodiments, the modulation of the levels of AHR agonists or antagonists is mediated through one or more of the following:
In some embodiments, indirect AHR modulators affect AHR activation through modulation of the expression of the AHR including e.g. HSP 90 inhibitors such as 17-allylamino-demethoxygeldanamycin (17-AAG), celastrol.
In some embodiments, indirect AHR modulators affect AHR activation by affecting binding partners/co-factors modulating the effects of AHR including e.g. estrogen receptor alpha (ESR1).
Examples of AHR modulators are listed in U.S. Pat. No. 9,175,266, US2019/225683, WO2019101647A1, WO2019101642A1, WO2019101643A1, WO2019101641A1, WO2018146010A1, AU2019280023A1, WO2020039093A1, WO2020021024A1, WO2019206800A1, WO2019185870A1, WO2019115586A1, EP3535259A1, WO2020043880A1 and EP3464248A1, all of which are incorporated by reference in their entirety.
In some embodiments, an effective amount of a AHR signaling modulator is about 0.01 mg/kg to 100 mg/kg. In other embodiments, the effective amount of an AHR signaling modulator is about 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.2 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 8 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 150 mg/kg, 175 mg/kg or 200 mg/kg of AHR signaling modulator.
Another aspect of the disclosure relates to a method of treating and/or preventing an AHR-related disease or condition in a cell in a patient in need of said treatment, comprising performing a method according to the present invention, and providing a suitable treatment to said patient, wherein said treatment is based, at least in part, on the results of the method according to the present invention, such as providing a compound as identified or monitoring a treatment comprising the method(s) as described herein.
Another aspect of the present disclosure relates to a diagnostic kit comprising materials for performing a method according to the present invention in one or separate containers, optionally together with auxiliary agents and/or instructions for performing said method.
Another aspect of the instant disclosure is directed to screening for or identifying compounds which modulate AHR activity. Another aspect of the instant disclosure is directed to methods for determining the effects of a compound on AHR activation status of a cell.
In some embodiments, a cell is treated with a candidate compound, and in the cell, a biological state of IL4I1 is determined/measured. In some embodiments, the biological state of IL4I1 in the biological sample is compared to the biological state of IL4I1 in a control sample. In some embodiments, the biological state is IL4I1 RNA expression.
In some embodiments, the candidate compound is categorized as an inhibitor of AHR signaling when the biological state of IL4I1 from the sample treated with a candidate compound is less than the biological state of IL4I1 from a control sample, and the candidate compound is categorized an activator of AHR signaling when the biological state the biological state of IL4I1 from the sample treated with a candidate compound is more than the biological state of IL4I1 from a control sample.
In some embodiments, a candidate compound is characterized as an AHR activator when it leads to at least 1.5 absolute fold upregulation in the biological state of IL4I1. In some embodiments, a candidate compound is characterized as an AHR activator when it leads to at least 2 absolute fold, at least 2.5 absolute fold, at least 3 absolute fold, at least 3.5 absolute fold, at least 4 absolute fold, at least 4.5 absolute fold, or at least 5 absolute fold upregulation in the biological state of IL4I1.
In some embodiments, a candidate compound is characterized as an AHR inhibitor when it leads to at least 0.67 absolute fold down-regulation in the biological state. In some embodiments, a candidate compound is characterized as an AHR inhibitor when it leads to at least 1 absolute fold, 2 absolute fold, at least 2.5 absolute fold, at least 3 absolute fold, at least 3.5 absolute fold, at least 4 absolute fold, at least 4.5 absolute fold, or at least 5 absolute fold down-regulation in the biological state.
The phrase “fold change” refers to the ratio between the value of a specific biomarker in two different conditions. In some embodiments, one of the two conditions could be a control. The phrase “absolute fold change” (which includes “absolute fold upregulation” and “absolute fold downregulation”) is used herein in the case of comparing the log transformed value of a specific biomarker between two conditions. Absolute fold change is calculated by raising the exponent of the logarithm to the fold change value and then reporting the modulus of the number.
Various aspects of the present disclosure may be embodied as a program, software, or computer instructions embodied or stored in a computer or machine usable or readable medium, or a group of media which causes the computer or machine to perform the steps of the method when executed on the computer, processor, and/or machine. A program storage device readable by a machine, e.g., a computer readable medium, tangibly embodying a program of instructions executable by the machine to perform various functionalities and methods described in the present disclosure is also provided.
In some embodiments, the present disclosure includes a system comprising a CPU, a display, a network interface, a user interface, a memory, a program memory and a working memory (
The term “processor” may include a single core processor, a multi-core processor, multiple processors located in a single device, or multiple processors in wired or wireless communication with each other and distributed over a network of devices, the Internet, or the cloud. Accordingly, as used herein, functions, features or instructions performed or configured to be performed by a “processor”, may include the performance of the functions, features or instructions by a single core processor, may include performance of the functions, features or instructions collectively or collaboratively by multiple cores of a multi-core processor, or may include performance of the functions, features or instructions collectively or collaboratively by multiple processors, where each processor or core is not required to perform every function, feature or instruction individually. The processor may be a CPU (central processing unit). The processor may comprise other types of processors such as a GPU (graphical processing unit). In other aspects of the disclosure, instead of or in addition to a CPU executing instructions that are programmed in the program memory, the processor may be an ASIC (application-specific integrated circuit), analog circuit or other functional logic, such as a FPGA (field-programmable gate array), PAL (Phase Alternating Line) or PLA (programmable logic array).
The CPU is configured to execute programs (also described herein as modules or instructions) stored in a program memory to perform the functionality described herein. The memory may be, but not limited to, RAM (random access memory), ROM (read-only memory) and persistent storage. The memory is any piece of hardware that is capable of storing information, such as, for example without limitation, data, programs, instructions, program code, and/or other suitable information, either on a temporary basis and/or a permanent basis.
In some embodiments, the disclosure is directed to a processor is programmed to perform:
(a) comparing a biological state of Interleukin 4-Induced gene 1 (IL4I1) from a sample to the biological state of IL4I1 from a control sample; and
(e) determining the AHR activation state of biological sample based on the comparing step.
In some embodiments, the disclosure is directed to a computer-readable storage device comprises instructions to perform:
(a) comparing a biological state of Interleukin 4-Induced gene 1 (IL4I1) from a sample to the biological state of IL4I1 from a control sample; and
(e) determining the AHR activation state of biological sample based on the comparing step.
The present invention thus relates to the following items.
Item 1. A method for detecting a modulation of AHR in a cell or subject, comprising detecting a change of the biological state of IL4I1 in a biological sample derived from said cell or subject, wherein a change in said biological state of IL4I1 in said sample, when compared to a control sample, indicates an IL4I1-related modulation of AHR in said cell or subject.
Item 2. The method according to Item 1, wherein said modulation is selected from an activation or repression of AHR.
Item 3. The method according to Item 1 or 2, wherein said modulation is indicative for an AHR-related physiological or pathological condition in said cell or subject.
Item 4. The method according to Item 3, wherein said physiological or pathological condition is selected from intoxication, cancer, autoimmune disorders, degeneration, inflammation, infection, metabolic diseases and conditions, angiogenesis, drug metabolism, hematopoiesis, lipid metabolism, cell motility, immune modulation, stress conditions, for example, biological, mechanical and environmental stresses.
Item 5. The method according to any one of Items 1 to 4, wherein said biological state as detected is selected from mutations, nucleic acid methylation, copy numbers, expression, amount of protein, protein modifications, cellular localization, metabolites, in particular metabolites as produced by IL4I1, such as, for example, tryptophan degradation products, and a biological activity of IL4I1.
Item 6. The method according to any one of Items 1 to 5, wherein said biological sample is selected from a suitable sample comprising biological fluids, mammalian, for example human, cells, tissues, whole blood, cell lines, cellular supernatants, primary cells, IPSCs, hybridomas, recombinant cells, stem cells, and cancer cells, bone cells, cartilage cells, nerve cells, glial cells, epithelial cells, skin cells, scalp cells, lung cells, mucosal cells, muscle cells, skeletal muscles cells, striated muscle cells, smooth muscle cells, heart cells, secretory cells, adipose cells, blood cells, erythrocytes, basophils, eosinophils, monocytes, lymphocytes, T-cells, B-cells, neutrophils, NK cells, regulatory T-cells, dendritic cells, Th17 cells, Th1 cells, Th2 cells, myeloid cells, macrophages, monocyte derived stromal cells, bone marrow cells, spleen cells, thymus cells, pancreatic cells, oocytes, sperm, kidney cells, fibroblasts, intestinal cells, cells of the female or male reproductive tracts, prostate cells, bladder cells, eye cells, corneal cells, retinal cells, sensory cells, keratinocytes, hepatic cells, brain cells, kidney cells, and colon cells, and the transformed counterparts of said cells or tissues.
Item 7. The method according to any one of Items 1 to 6, wherein said subject is selected from a mammalian subject, for example a human subject, for example a human patient suffering from an AHR-related physiological or pathological condition.
Item 8. The method according to any one of Items 1 to 7, wherein said control sample is selected for example from a sample from a healthy subject or group of subjects.
Item 9. A method for screening for at least one modulator of the biological state of IL4I1, comprising contacting at least one candidate modulator compound with a biological sample, and detecting the modulation of the biological state of IL4I1 or a gene encoding for IL4I1, wherein said modulation or activity identifies a modulator of said biological state.
Item 10. The method according to Item 9, wherein said method further comprises detecting a change of a biological state of IL4I1 in a biological sample, wherein a change in the biological state of said IL4I1 in the presence of said at least one modulator compared to the absence of said at least one modulator identifies a modulator.
Item 11. The method according to Item 9 or 10, wherein said biological state as detected is selected from mutations, nucleic acid methylation, copy numbers, expression, amount of protein, protein modifications, cellular localization, metabolites, in particular metabolites as modulated by IL4I1, such as, for example, tryptophan degradation products, and the biological activity of IL4I1.
Item 12. The method according to any one of Items 9 to 11, wherein said modulator is selected from an inhibitor or an inducer of said biological state of IL4I1.
Item 13. The method according to any one of Items 9 to 12, wherein said method further comprises detecting a modulation of AHR.
Item 14. The method according to any one of Items 9 to 13, wherein said compound is selected from a proteinaceous domain, a small molecule, a peptide, antibodies, for example monoclonal antibodies binding IL4I1, an environmental substance, probiotic, toxin, aerosol, medicine, nutrient, galenic composition, plant extract, volatile compound, homeopathic substance, incense, pharmaceutical drug, vaccine, a compounds or compound mixture derived from organisms, for example animals, plants, fungi, bacteria, archaea, a chemical compound, a compound used in food or cosmetic industry, and a library of said compounds.
Item 15. A method for monitoring the modulation of the biological state of AHR in response to at least one compound, comprising performing a method according to any one of Items 1 to 8 on a biological sample that was contacted with an amount of said at least one compound, and wherein said biological sample is compared to a control sample that was not contacted with said amount of said compound.
Item 16. The method according to Item 15, wherein said biological samples are obtained through the course of a treatment, and/or are compared to a suitable control sample or a sample derived from a group of subjects or patients, as described herein.
Item 17. The method according to any one of Items 1 to 16, wherein said method further comprises the step of using said comparison for unsupervised clustering or supervised classification of said samples into subgroups of IL4I1 modulation, and optionally for further unsupervised clustering or supervised classification of said samples into different subgroups of AHR modulation.
Item 18. The method according to any one of Items 1 to 16, further comprising a stratification of said subject into a particular group of subjects or patient groups.
Item 19. The method according to any one of Items 1 to 18, wherein said method comprises using a high-throughput method.
Item 20. A diagnostic kit comprising materials for performing a method according to any one of Items 1 to 19 in one or separate containers, optionally together with auxiliary agents and/or instructions for performing said method.
Item 21. Use of a diagnostic kit according to Item 20 for a method according to any one of Items 1 to 19.
Item 22. A method for treating and/or preventing an AHR-related disease or condition in a cell, for example in a patient in need of said treatment, comprising performing a method according to any one of Items 1 to 19, and providing a suitable treatment to said patient, wherein said treatment is based, at least in part, on the results of said method.
The invention shall now be further described in the following examples with reference to the accompanying figures, nevertheless, without being limited thereto. For the purposes of the present invention, all references as cited herein are incorporated by reference in their entireties.
SEQ ID Nos: 1 to 26 show sequences of oligomers as used in the present invention.
Array datasets—The affymetrix microarray chips “human gene 2.0 ST” were analyzed using the oligo package and annotated using NetAffx (14). Raw CEL files were RMA normalized and summarized. Differential gene expression was performed using the limma pipeline for microarrays (15).
RNA-seq datasets—The harmonized FPKM data of The Cancer Genome Atlas (TCGA) tumor datasets were downloaded using TCGAbiolinks (16) from GDC (https://gdc.cancer.gov), and only patients with the identifier “primary solid tumor” were retained. The FPKM values were converted to Transcripts per Million (TPMs) (17), TPM data of normal tissues were downloaded from the Genotype-Tissue Expression dataset (GTEX—https://gtexportal.org/home/). All TPM values were log 2 transformed.
HEK293T, LN-229, Tao BpRc1 and U-87MG were obtained from ATCC. CAS-1 and U-251MG were from ICLC and ECACC, respectively. CAS-1, HEK293T, LN-229, U-87MG and U-251MG were cultured in phenol-red free high glucose DMEM medium (Gibco, 31053028) supplemented with 10% FBS (Gibco, 10270106), 2 mM L-glutamine (Gibco, 25030-024), 1 mM sodium pyruvate (Gibco, 11360-039), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco, 15140-122) (henceforth, referred to as complete DMEM). Tao BpRc1 cells were cultured as above, but with complete phenol-red free DMEM and 5 μg/mL tetracycline (Sigma-Aldrich, T3383). For translocation assays medium with 10% Tet System Approved FBS (Clontech, 631107) was used. Cells were cultured at 37° C. and 5% CO2.
Human IL4I1 cDNA clone flanked by Gateway compatible recombination sites was purchased from MyBiosource (MBS1270935). The cDNA clone was recombined into Lentivirus compatible Gateway expression vector pLX301 (a gift from D. Root, Addgene plasmid 25895)18. Production of Lentiviruses was achieved by transfecting HEK293T with pMD2.G (a gift from D. Trono, Addgene plasmid 12259), psPAX2 (a gift from D. Trono, Addgene plasmid 12260), and lentiviral plasmid, using FuGENE HD (Promega, E2311), according to the manufacturer's protocol. Viral supernatants were harvested at 48 h and 72 h, pooled and filtered through a 0.45 μm pore filter. Stable IL4I1 overexpressing (pLX301-IL4I1) and control (pLX301) cell lines were generated by infecting U-87MG and U-251MG cells for 24 hours with respective viral supernatants in presence of 8 μg/mL polybrene (Merck Millipore, TR-1003-G), followed by selection with medium containing 1 μg/mL puromycin (AppliChem, A2856). Stable overexpression of IL4I1 was confirmed by qRT-PCR, western blot and IL4I1 enzymatic activity.
Stable knockdown of AHR in U-87MG cells was achieved using shERWOOD UltramiR Lentiviral shRNA targeting AHR (transOMIC Technologies, TLHSU1400-196-GVO-TRI). Glioma cells were infected with viral supernatants containing either shAHR or shControl (shC) sequences to generate stable cell lines. shERWOOD UltramiR shRNA sequences are:
siRNA mediated gene knockdown of IL4I1 was carried out using ON-TARGETplus Human SMARTpool siRNA reagent (Dharmacon, L-008109-00-0005). siRNA mediated gene knockdown of AHR was carried out using ON-TARGETplus Human SMARTpool siRNA reagent (Dharmacon, L-004990-00-0005). siRNA transfections were done with Lipofectamine RNAiMAX (Thermo Fisher Scientific, 13778100), following the manufacturer's protocol. ON-TARGETplus Non-targeting Pool siRNA (Dharmacon, D-001810-10-05) was used as control.
Stably transfected tao BpRc1c cells, expressing a GFP-tagged Ahr under tetracycline control, were used to visualize nuclear translocation of Ahr. The murine Ahr was cloned into the pEGFP-C1 vector (CLONTECH, Palo Alto, Calif.) including a tet-off expression system (pRevTRE, CLONTECH). The Phoenix packaging line was used for retroviral transfection into murine hepatoma tao BpRc1 cells deficient of endogenous Ahr expression.
For treatment of adherent cells with established and hypothetical AHR ligands, 4×105 cells per well were seeded in six well plates and incubated for 24 h prior to treatment. Non-adherent cells were seeded in 24 well plates at 5×105 cells in 1 mL and treated immediately. For verification of the generated AHR signature, cells were treated with the established AHR agonist Kyn (50 μM, SigmaAldrich, K8625) for 24 h. In order to investigate the potential of direct and downstream IL4I1 metabolites to activate the AHR, cells were treated with I3P (3.125 μM to 100 μM, Sigma-Aldrich, 17017), HPP (8 μM to 1000 μM, Sigma-Aldrich, 114286), PP (8 μM to 1000 μM, Alfa Aesar, L11934), kynurenic acid (50 μM, Sigma-Aldrich, K3375), indole-3-lactic acid (25 μM to 100 μM, Sigma-Aldrich, 15508), 3-indoleacetic acid (25 μM to 100 μM, Sigma-Aldrich, 12886), indole-3-carboxaldehyde (6.25 μM to 100 μM, Sigma-Aldrich, 129445) and supernatants of U-87MG or U-251MG control and IL4I1 expressing cells for 24 h. When using the AHR antagonist SR1 (1 μM, Merck Millipore, 182706), cells were treated for 24 h alone or in combination with AHR ligands. DMSO was used for dissolving all compounds such that its final concentration in culture medium did not exceed 0.2%.
For gene and protein expression experiments involving U-87MG and U-251MG control and IL4I1 expressing cells, 4×105 cells per well were seeded in 2 mL in six well plates, and incubated for 72 or 120 h. For metabolomics experiments, cells were seeded at a density of 4×105 cells per well in 2 mL of complete DMEM in six well plates and incubated for 24 h. In cases where more cells and supernatant were needed, 2.6×106 cells per well were seeded in 13.3 mL of complete DMEM in 10 cm dishes and incubated for 24 h. After 24 h, cells were washed once with PBS, 2 or 13.3 mL of fresh FBS-free DMEM were added (depending on the well size and cell density used) and cells were incubated for 120 h. Sample preparation was adapted from previous studies19,20. Briefly, supernatants were snap frozen in liquid nitrogen and stored at −80° C. until metabolite measurement. Plates containing cells were quickly washed once with 37° C. pre-heated cell culture grade water, quenched with liquid nitrogen and stored at −80° C. until metabolite measurement.
For experiments where IL4I1 was knocked down in CAS-1 cells, 4×105 cells per well in six well plates were seeded and incubated for 24 h. Cells were transfected with respective control or targeting siRNA. Complete DMEM was replaced with 1.5 mL of FBS-free DMEM 24 h post-transfection and cells were incubated for 72 h.
Total RNA was harvested from cultured cells using the RNeasy Mini Kit (Qiagen, 80204) followed by cDNA synthesis using the High Capacity cDNA reverse transcriptase kit (Applied Biosystems, 4368813). A StepOne Plus real-time PCR system (Applied Biosystems) was used to perform real-time PCR of cDNA samples using SYBR Select Master mix (Thermo Scientific, 4309155). Data was processed and analysed using the StepOne Software v 2.3. Relative quantification of target genes was done against RNA18S as reference gene using the 2ΔΔCt method. Human primer sequences are listed in table 2 as follows.
For AHR translocation assays, protein content in the nuclear and the cytoplasmic fractions of LN-229 glioma cells was compared by immunoblotting. LN-229 cells were treated with supernatants of U-251MG control or IL4I1 expressing cells (120 h) for 4h. Lysates were snap frozen in liquid nitrogen and thawed three times following 10 cycles of ultrasonication after each freeze-thaw cycle. To isolate protein from the two different cellular fractions NE-PER™ Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific Inc.) were used. Extraction was performed following the manufacturer's instructions. Nuclear specific Lamin A served as control for appropriate fractionation and was detected using polyclonal rabbit anti-Lamin A (1:500, BioLegend), respectively. AHR was detected using the primary mouse monoclonal anti-AHR antibody clone RPT1 (Abcam, Berlin, Germany).
For induction of GFP-Ahr expression in the transgenic tao BpRc1c cells, cells were taken off tetracycline 24 h before translocation assays. Assays were performed in black clear bottom 96-well plates (BD, #353219) with 7500 cells/well in 150 μl/well. Metabolites were added in 50 μL/well induction medium. Cells were exposed for 4h to 25 μM PP, HPP, and I3P respectively. Medium was discarded and cells fixed with pre-warmed 3.7% formaldehyde in PBS (10 min at RT). After fixation cells were washed with detergent buffer (DB, 0.01% Tween20 in PBS, Sigma Aldrich), followed by permeabilization with 0.1% Triton X-100 in PBS (Sigma Aldrich) for 15 min at RT. Cells were washed twice with DB and incubated with 0.4 ng/ml Hoechst 33342 (Sigma Aldrich) for 30 min at RT protected from light. After washing with DB and PBS cells were stored in PBS at 4° C. until translocation analysis. Translocation by KynA was monitored by live cell imaging after 3 h of exposure including the appropriate negative medium control. Translocation of Ahr by the different metabolites was monitored on a BD Pathway Imager 855.
Consumption of phenylalanine, tyrosine and Trp by IL4I1-expressing and non-expressing U-87MG and U-251MG cells was assessed by quantification of the amino acids in the cell culture supernatants after 120 h incubation. For phenylalanine and tyrosine detection, amino acids were labeled with the fluorescent dye AccQ-Tag™ (Waters) according to the manufacturer's protocol. The derivatization product was separated at 42° C. on an Acquity BEH C18 column (Waters) using an Acquity H-class UPLC system (Waters) coupled to an Acquity fluorescence detector (FLR) (Waters). Samples were analyzed on the UPLC as described before by Yang et. al., 201521. For analyses of Trp consumption, supernatants were mixed with an equal volume of 12% perchloric acid and incubated on ice for 10 min. Prior to analysis, samples were centrifuged for 10 min at 4° C. and 16,400 g to precipitate proteins and remove remaining cell debris. Metabolites were then separated by reversed phase chromatography on an Acquity HSS T3 column (100 mm×2.1 mm, 1.7 μm, Waters) connected to an Acquity H-class UPLC system (Waters). The column was heated to 37° C. and equilibrated with 5 column volumes of 100% solvent A (20 mM sodium acetate, 3 mM zinc acetate, pH 6) at a flow rate of 0.55 mL/min. Clear separation of Trp was achieved by increasing the concentration of solvent B (acetonitrile) in solvent A as follows: 4 min 0% B, 10 min 5% B, 13 min 15% B, 15 min 25% B, and return to 0% B in 3 min. Trp was detected by fluorescence (Acquity FLR detector, Waters, excitation: 254 nm, emission: 401 nm). Standards were used for quantification (Sigma). Data acquisition and processing was performed with the Empower3 software suite (Waters). We took an untargeted metabolomics approach to identify metabolites that were differentially abundant in supernatants of IL4I1-expressing versus non-expressing U-87MG and U-251MG cells cultured for 120 h. To this end, 50 μl of cell culture supernatants were mixed with 200 μl ice-cold acetonitrile by vortexing followed by incubation at −20° C. for 1 h. Samples were centrifuged for 15 min at 4° C. and transferred into TruView UPLC-MS vials (Waters). A pool sample was prepared by mixing equal volumes of all samples. Samples were measured using an I-class UPLC system coupled to a Vion IMS QTof MS (Waters). Metabolites were separated using either a Cogent Diamond Hydride 2.0 column (150×2.1 mm, 2.2 μm; MicroSolv USA) or a HSS T3 column (100×2.1 mm, 1.8 μm; Waters). For instrument control and acquisition of MS data UNIFI 1.8.2 (Waters) was used. Follow-up data analyses were performed using Progenesis QI (Waters). ILA was detected at 204.0662 Da (neg. mode; expected monoisotopic mass: 205.0739 Da; deviation −2 ppm) and identified by the expected fragment ions at 116.0495, 128.0495, 130.0652 and 204.0655 Da. Selected differentially abundant Trp-, phenylalanine- and tyrosine-derived metabolites (IAA, I3CA, KynA, PP, HPP, HBA) and further downstream transformation products (Kyn, PAA, HPAA) were identified by comparing their fragmentation patterns resulting from suspect LC-MS measurements using an HPLC (Agilent 1290) coupled to a triple quad MS (Agilent 6460) with external standards.
For targeted quantification of the metabolites, MRM mode was used. For all test compounds 10 mM stock solutions were prepared by gravimetrically adding the required amount into 1.5 mL Eppendorf safe-lock tubes and dissolving the test compound in 1 mL DMSO. For each compound, stock solutions covered a concentration range from 10 mM to 0.039 mM. For quantification of the metabolites, 300 μL of each bioassay supernatant was added into Eppendorf safe-lock tubes. Associated calibration samples were prepared by adding 300 μL cell culture media and 1 μL of test compound stock solution into Eppendorf safe-lock tubes. Subsequently, 300 acetonitrile was added to trigger precipitation of media components. All samples were centrifuged at 8000 rpm for 4 min and 150 μL of the supernatants was transferred into 1.5 mL glass vials equipped with 200 μL glass inserts for HPLC analysis. 5 μl of the sample was injected for the analysis. Water and acetonitrile with 0.1% formic acid were used as eluent A and B, respectively for HPLC separation for 5 min with a flowrate of 0.5 mL/min. Separation was achieved using a 50 mm long Poroshell 120 EC-C18 2.7 micron column (Agilent). The Agilent Jetstream ESI source was set to gas and gas sheath temperature of 300° C., with a gas flow of 10 L/min and sheath gas flow of 11 L/min. The nebulizer pressure was set to 55 psi and capillary voltage at 2000 V throughout the run. For instrument control and data acquisition MassHunter software suite (Agilent) was used.
U-87MG and U-251MG cells stably expressing IL4I1 and control transduced counterparts were lysed in 0.1% Triton X-100/PBS. Human tissue obtained from resection of metastatic melanoma was lysed in 1% Triton X-100/PBS by shaking with stainless steel beads in a Mixer Mill MINI 301 for two cycles of 1 min at 40 Hz. IL4I1 activity was determined by measuring H2O2 production via Amplex® Red fluorescence (excitation at 530 nm and emission at 590 nm) every minute for 60 minutes in black 96-well plates using a CLARIOstar® (BMG LABTECH) plate reader. Reactions were prepared in PBS and contained 50 μM Amplex® Red (Cayman Chemicals, #Cayl0010469), 0.1 U/mL HRP (Merck Millipore, #516531) and amino acids as IL4I1 substrates as indicated in figure legends. IL4I1 independent H2O2 production was assessed in absence of amino acids and subtracted from activity obtained in presence of substrate. IL4I1 mediated H2O2 production was calculated using an H2O2 calibration curve (0-10 μM final) and normalized to sample protein content as quantified by Bradford assay.
Graphical and statistical analysis of gene (real time-PCR) and protein expression data, as well as metabolite data were done using GraphPad Prism software versions 6.0 and 8.0. Unless otherwise indicated, data represents the mean±S.E.M of at least 3 independent experiments. In cases where data was expressed as fold of change, these values were Log 10 transformed and the resulting values were used for statistical analysis. Depending on the data, the following statistical analyses were applied: two-tailed student's t-test (paired or unpaired), one-way ANOVA with Tukey's multiple comparisons test and repeated measures ANOVA with Dunnett's multiple comparisons test. Significant differences were reported as *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. n. s. indicates no significant difference.
When comparing the expression levels of Trp degrading enzymes in normal (GTEX) and tumor tissue, the inventors found that IL4I1 expression was enhanced in cancer tissues compared to normal tissues, similar to IDO1 and TDO2, other tryptophan degrading enzymes that are implicated in activating AHR, (
Next, the inventors set out to investigate how IL4I1 activates the AHR. In keeping with previous reports, IL4I1 expression reduced the levels of phenylalanine, tyrosine and tryptophan (
The IL4I1-expressing cells showed high levels of PP and HPP as well as their downstream metabolites phenyl acetic acid (PAA), 4-hydroxybenzaldehyde (HBA) and hydroxyphenyl acetic acid (HPAA) (
| Number | Date | Country | Kind |
|---|---|---|---|
| 19168304.4 | Apr 2019 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2020/060259 | 4/9/2020 | WO | 00 |
